NEW YORK, July 3 – Roche Diagnostics has entered into a 15-year agreement to purchase, use and resell CombiMatrix’s biochips, the companies announced Tuesday.

The worldwide, non-exclusive deal includes minimum payments by Roche to CombiMatrix during the first three years of the agreement, including royalties, payments for products, and R&D projects. The deal also stipulates that the companies develop a joint platform technology for standardized biochips.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.